Literature DB >> 26387928

A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study.

Clare L Atzema1, Paul Dorian2, Jiming Fang3, Jack V Tu4, Douglas S Lee5, Alice S Chong3, Peter C Austin6.   

Abstract

STUDY
OBJECTIVE: The high volume of patients treated in an emergency department (ED) for atrial fibrillation is predicted to increase significantly in the next few decades. Currently, 11% of these patients die within a year. We sought to derive and validate a complex model and a simplified model that predicts mortality in ED patients with atrial fibrillation.
METHODS: This population-based, retrospective cohort study included 3,510 adult patients with a primary diagnosis of atrial fibrillation who were treated at 24 hospital EDs in Ontario, Canada, between April 2008 and March 2009. The main outcome was 30-day all-cause mortality.
RESULTS: In the derivation cohort (n=2,343; mean age 68.8 years), 2.6% of patients died within 30 days of the ED visit versus 2.7% in the validation cohort (n=1,167; mean age 68.3 years). Variables associated with mortality in the complex model included age, presenting pulse rate and systolic blood pressure, presence of chest pain, 2 laboratory results (positive troponin result and creatinine level greater than 200 μmol [2.26 mg/dL]), 4 comorbidities (smoking, chronic obstructive pulmonary disease, cancer, and dementia), an increased bleeding risk, and a second acute ED diagnosis (in addition to atrial fibrillation). Observed 30-day mortality in the 5 risk strata that were defined by the predicted probability of death were 0.44%, 0.41%, 0.23%, 1.61%, and 10.3%. The c statistics were 0.88 and 0.87 in the derivation and validation cohorts, respectively. The a priori-selected 6-variable model, TrOPs-BAC, included a positive Troponin result, Other acute ED diagnosis, Pulmonary disease (chronic obstructive pulmonary disease), Bleeding risk, Aged 75 years or older, and Congestive heart failure. The c statistic for the simplified model was 0.81 in both the derivation and validation cohorts.
CONCLUSION: Using a population-based sample, we derived and validated both a complex and a simplified instrument that predicts mortality after an emergency visit for atrial fibrillation. These may aid clinicians in identifying high-risk patients for hospitalization while safely discharging more patients home.
Copyright © 2015 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26387928     DOI: 10.1016/j.annemergmed.2015.07.017

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

1.  Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation.

Authors:  Clare L Atzema; Cynthia A Jackevicius; Alice Chong; Paul Dorian; Noah M Ivers; Ratika Parkash; Peter C Austin
Journal:  CMAJ       Date:  2019-12-09       Impact factor: 8.262

Review 2.  Management and Disposition of Atrial Fibrillation in the Emergency Department: A Systematic Review.

Authors:  Justin L Vandermolen; Murrium I Sadaf; Anil K Gehi
Journal:  J Atr Fibrillation       Date:  2018-06-30

3.  Predictors of Acute Atrial Fibrillation and Flutter Hospitalization across 7 U.S. Emergency Departments: A Prospective Study.

Authors:  Bory Kea; E Margaret Warton; Dustin W Ballard; Dustin G Mark; Mary E Reed; Adina S Rauchwerger; Steven R Offerman; Uli K Chettipally; Patricia C Ramos; Daphne D Le; David S Glaser; David R Vinson
Journal:  J Atr Fibrillation       Date:  2021-02-28

4.  Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study.

Authors:  So-Ryoung Lee; Eue-Keun Choi; Seo-Young Lee; Euijae Lee; Kyung-Do Han; Myung-Jin Cha; Woon Yong Kwon; Sang Do Shin; Seil Oh; Gregory Y H Lip
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.